Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 18/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 18/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774668 | 0.96 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6768921 | 0.93 | CCR3 (0.88) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6774732 | 0.93 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18840948 | 0.93 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6773194 | 0.93 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18840954 | 0.93 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18844264 | 0.93 | CCR3 (0.86) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6774787 | 0.90 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7662809 | 0.89 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7666626 | 0.89 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | WATSON PAUL S (US) | 2003-07-31 | — | — | US | claimed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | claimed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-6706735-B2 | NITROGEN COMPOUNDS SUCH AS N-(3-(4-BENZYL-2-PIPERIDINYL)PROPYL )-N'-(3-CYANOPHENYL)UREA, USED AS CHEMOTACTIC CYTOKINE CONTROLLERS ADMINISTERED FOR PROPHYLAXIS OF ASTHMA, ALLERGIES AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | WATSON PAUL S (US) | 2003-07-31 | — | — | US | disclosed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | CCR3 1/4885SLC6A2 2615/4885SLC6A4 2372/4885 |
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | CCR3 1/4885SLC6A2 3713/4885SLC6A4 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.